Type 1 tyrosinemia in Finland: a nationwide study
Abstract Background Introduction of nitisinone and newborn screening (NBS) have transformed the treatment of type 1 tyrosinemia, but the effects of these changes on the long-term outcomes remain obscure. Also, the predictors for later complications, the significance of drug levels and the normalizat...
Main Authors: | Linnea Äärelä, Pauliina Hiltunen, Tea Soini, Nina Vuorela, Heini Huhtala, Pasi I. Nevalainen, Markku Heikinheimo, Laura Kivelä, Kalle Kurppa |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-10-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-020-01547-w |
Similar Items
-
Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)
by: Das AM
Published: (2017-07-01) -
NTBC Treatment Monitoring in Chilean Patients with Tyrosinemia Type 1 and Its Association with Biochemical Parameters and Liver Biomarkers
by: Karen Fuenzalida, et al.
Published: (2021-12-01) -
Clinical and para clinical findings in the children with tyrosinemia referring for liver transplantation
by: Seyed Mohsen Dehghani, et al.
Published: (2013-01-01) -
The Importance of Succinylacetone: Tyrosinemia Type I Presenting with Hyperinsulinism and Multiorgan Failure Following Normal Newborn Screening
by: Jessica R. C. Priestley, et al.
Published: (2020-05-01) -
Treatment adherence in tyrosinemia type 1 patients
by: Domingo González-Lamuño, et al.
Published: (2021-06-01)